Psoriasis patients who will receive systemic treatment (mainly methotrexate)

Psoriasis patients who will receive a biological treatment

Patients with major depression who will receive an antidepressant treatment

A blood collection will be performed to collect serum and PBMC (peripheral blood mononuclear cells). Serum samples will be centrifuged at 1750 rpm for 10 minutes, the supernatant will be collected and frozen at -20 ° C. For PBMC, Ficoll gradient centrifugation of blood samples with anticoagulant will be carried out. Once the PBMCs are separated, they will be frozen with 20% DMSO in RPMI culture doctor with 20% fetal calf serum (FCS) and stored in liquid nitrogen. Blood samples will also be obtained for the total extraction of RNA with 3 ml of Paxgene® tubes, processed and frozen at -80 ° C

Psoriasis

Neuroinflammation

Major Depressive Disorder

Cognitive Symptom

Immunological Abnormality

Sociodemographic variables: Sex / Age / Marital status / Level of studies completed / Employment status.
General clinical variables: Body mass index (BMI), Medical comorbidities and Charlson Comorbidity Index, Active drug treatments
Clinical psoriasis variables: BSA, PASI, ScalpPASI, PPPASI, DLQI, time since the diagnosis of psoriasis, previous treatments for psoriasis.
Clinical depression variables: Psychiatric diagnoses according to clinical interview and DSM-5 criteria, age of onset and time of evolution from the first episode of major depression, time of evolution of the current episode of major depression, previous treatments for depression.
Psychopathological variables: HADS, PHQ-9, MADRS, GAD-7, SHAPS, The Irritability Questionnaire, PSS, FSS, MoCA.
Immunological and biochemical variables: Acute phase biomarkers, Proinflammatory cytokines, Anti-inflammatory cytokines, HPA axis, Microglia activation, Neurogenesis.
Result variables: Changes in PASI or MADRS scores

Sociodemographic variables

Neuroinflammation, Affective and Cognitive Symptoms in Major Depression and Psoriasis

Neuroinflammation and Affective and Cognitive Symptoms in Patients Suffering From Major Depression and Psoriasis and Their Evolution With Treatment: A Prospective Study

To evaluate the relationship of psychiatric symptoms (affective symptoms, fatigue, cognitive deficits) and markers of inflammation, HPA axis, oxidative and nitrosative stress, gliosis and neurogenesis in both groups of psoriasic and depressive patients.

To evaluate the changes of psychiatric symptoms (affective symptoms, fatigue, cognitive deficits) and markers of inflammation, HPA axis, oxidative and nitrosative stress, gliosis and neurogenesis, after treatment for psoriasis with systemic or biological treatment of psoriasis and with antidepressant treatment for major depression.

To assess the relationship between the variations of the biological markers of inflammation, HPA axis, oxidative and nitrosative stress, gliosis and neurogenesis and the course of psychiatric comorbidity in relation to the different anti-inflammatory treatments for psoriasis.

To evaluate the relationship between the course of major depressive illness with treatment and biomarkers of inflammation, HPA axis, oxidative and nitrosative stress, gliosis and neurogenesis

Germans Trias i Pujol Hospital

Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Erdheim-Chester Disease

Dabrafenib Mesylate

Quality-of-Life Assessment

Questionnaire Administration

Trametinib Dimethyl Sulfoxide

M D Anderson Cancer Center

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600 Mutation Positive Lesions in Erdheim Chester Disease

Measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Response to therapy will be evident on follow up imaging studies revealing a decrease in lesion size of 30% or more, which is defined as a partial response as per RECIST criteria, when compared to baseline studies.

Assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Will be reported using Kaplan-Meier curves and appropriate 95% confidence intervals.

Patients will be evaluated using the multi-dimensional fatigue inventory.

Patients will be evaluated using the 6 minute walk test, single leg stance, and functional reach and grip strength using a dynamometer.

Patients will be evaluated using the human activity profile and activity card sort.

Patients will be evaluated using the comparative pain scale.

Patients will be evaluated using the the group peg board test.

Improvement of patients' overall quality of life will be evidence of response, and assessments will be made at baseline and throughout the trial, as well as at the conclusion of the trial, to evaluate for any improvement in quality of life. Patients will be evaluated using the National Institute of Neurological Disorders and Stroke-Neuro-Quality of Life scale.

Resistance to therapy will be evaluated through imaging studies and patient follow up for at least one year, but this is not expected with the combination therapy.

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

dimethyl sulfoxide/fatigue

Neuroinflammation, Affective and Cognitive Symptoms in Major Depression and Psoriasis

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht